Zhen-xin Zeng

Dongjie Road 134
Fuzhou, 350001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A network meta-analysis of first-line treatment options for patients with Child-Pugh class B functional hepatocellular carcinoma: comparison of efficacy and safety.

A network meta-analysis of first-line treatment options for patients with Child-Pugh class B functional hepatocellular carcinoma: comparison of efficacy and safety.

Journal: Frontiers in pharmacology

Published: September 15, 2025

HAIC plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus.

HAIC plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus.

Journal: Hepatology international

Published: August 15, 2025

Letter to the Editor: Immortal time bias in the management of patients with HCC who achieved CR following immunotherapy-based systemic therapy.

Letter to the Editor: Immortal time bias in the management of patients with HCC who achieved CR following immunotherapy-based systemic therapy.

Journal: Hepatology (Baltimore, Md.)

Published: June 12, 2025

Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors.

Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors.

Journal: Journal of inflammation research

Published: February 02, 2025

Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.

Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.

Journal: The oncologist

Published: January 15, 2025

Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.

Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.

Journal: Liver cancer

Published: August 13, 2024

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study.

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study.

Journal: Journal of hepatocellular carcinoma

Published: June 01, 2024

Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study.

Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study.

Journal: Journal of hepatocellular carcinoma

Published: May 06, 2024

Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review.

Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review.

Journal: Oncology research and treatment

Published: March 24, 2024

Reply to: "Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed".

Reply to: "Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed".

Journal: Hepatology international

Published: March 21, 2024

Long-term surgical outcomes of bile duct tumor thrombus versus portal vein tumor thrombus for hepatocellular carcinoma: a propensity score matching analysis.

Long-term surgical outcomes of bile duct tumor thrombus versus portal vein tumor thrombus for hepatocellular carcinoma: a propensity score matching analysis.

Journal: Frontiers in oncology

Published: January 17, 2024

Surgical outcomes of hepatocellular carcinoma with extrahepatic bile duct tumor thrombus: a multicenter study.

Surgical outcomes of hepatocellular carcinoma with extrahepatic bile duct tumor thrombus: a multicenter study.

Journal: Frontiers in oncology

Published: September 09, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026